AGMB

TentativeAI Memo

AgomAb Therapeutics

As of 2026-10-02/Confidence low

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

low

Horizon

—

Key catalyst

NOV-ERA Phase 2b initiation • 2026-12-31

Base target: $9 / p=45% prob

Biggest risk

The extension was open-label and its optional endoscopy data were inadequate for reliable interpretation. Neither ontunisertib nor AGMB-447 has established efficacy or safety for approval; Phase 2 execution and cash consumption remain material risks. The 22.07% October 1 close-to-close decline despite the favorable release argues against assuming the readout is an immediate valuation unlock. [#PR-2026-10-01] Company release Historical prices

Invalidation

Break below $6 or thesis failure.

What would change my mind?

The STENOVA extension offers encouraging longer-term safety and disease-control signals, while the Phase 1 IPF cohort supports advancing a second program. June 30 cash and investments of €252 million were expected by management to fund operations into the first half of 2029. [#PR-2026-10-01] Company release [#IR-2026-08-06] Half-year results

Research note

Recommendation

—

Confidence

low

As of

2026-10-02

Base target

p=45%

Bull target

$14

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

STENOVA extension readout and sharp price reversal
NOV-ERA controlled efficacy assessment
The STENOVA extension offers encouraging longer-term safety and disease-control signals, while the Phase 1 IPF cohort supports advancing a second program.

BearKey bullets

AGMB-447 IPF evidence comes from 10 patients over 14 days; cough and bronchospasm were reported, and higher-dose adverse events were more frequent.
[#PR-EARNINGS-2026-09-14] Company release
Only 37 of 49 extension entrants completed 48 weeks, and optional Week 48 endoscopy data were too limited for reliable interpretation.

WatchKey bullets

NOV-ERA Phase 2b initiation

Summary

High-level snapshot

Recommendation

Model confidence

low

Timeframe

Asset

Equity

Trigger

Base case: $9 (p=45%)

Target spread vs base: +56% / -39%

Scenario probabilities

Bull Target: $14 (p=25%)Base Target: $9 (p=45%)Bear Target: $6 (p=30%)

Commentary

News tone on the clinical results was constructive, but AGMB reversed a reported premarket gain and closed October 1 down 22.07% at $8.65. No causal explanation for the full-day decline or verified post-readout analyst target or estimate revision is available. The numeric sentiment, options, short-interest and employee fields are unavailable-data placeholders, not measured neutral values. Company release Historical prices

As of 2026-10-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

STENOVA extension readout and sharp price reversal
NOV-ERA controlled efficacy assessment

Scenarios

Bull Target (Scenario probability)

$14 / p=25% prob

Base Target (Scenario probability)

$9 / p=45% prob

Bear Target (Scenario probability)

$6 / p=30% prob

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
NOV-ERA Phase 2b initiation
Agomab says regulatory filings are complete and plans to initiate the approximately 320-patient, placebo-controlled ontunisertib study in the coming months. First dosing, enrollment and eventual efficacy remain unconfirmed; the open-label extension cannot establish placebo-controlled benefit. [#PR-2026-10-01] Company release
Prob 65.00% • Move 10.00% • Priced-in 45.00%
EVENT2026-12-31
INSPIRIA Phase 2 initiation
Following Phase 1 target-engagement and tolerability findings in a 10-patient IPF cohort, Agomab submitted the clinical trial application and intends to initiate the approximately 120-patient AGMB-447 study before year-end. The short Phase 1 exposure did not establish clinical efficacy or longer-term safety. [#PR-EARNINGS-2026-09-14] Company release
Prob 65.00% • Move 8.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

STENOVA extension readout and sharp price reversal
2026-10-01
Agomab reported that 49 patients entered the open-label extension, 37 completed it, and one Crohn’s disease-related dilation and no surgeries occurred during treatment. The company said optional endoscopy data were too limited for reliable interpretation. Shares closed October 1 at $8.65, down 22.07% from $11.10 on September 30; the price move does not establish why investors sold. [#PR-2026-10-01] Company release Historical prices
Prob 100% • Move -22% • Priced-in 100%

Long-term Catalysts

Months to a year

NOV-ERA controlled efficacy assessment
2028-12-31
NOV-ERA’s primary endpoint assesses endoscopic passability at Week 24. The sponsor’s trial registry lists December 31, 2028 as an estimated primary-completion date, not a promised results-release date. A controlled result could materially clarify the open-label STENOVA signals, but enrollment, timing and efficacy remain uncertain. [#PR-2026-10-01] Company release Sponsor trial registry
Prob 50% • Move 25% • Priced-in 20%

Risks

AGMB-447 IPF evidence comes from 10 patients over 14 days; cough and bronchospasm were reported, and higher-dose adverse events were more frequent. [#PR-EARNINGS-2026-09-14] Company release
Only 37 of 49 extension entrants completed 48 weeks, and optional Week 48 endoscopy data were too limited for reliable interpretation. [#PR-2026-10-01] Company release
Open-label STENOVA extension lacks a concurrent control arm; cross-trial event-rate comparisons cannot establish treatment benefit. [#PR-2026-10-01] Company release
Phase 2 trial initiation, enrollment, efficacy, future financing needs and the projected cash runway are uncertain. [#IR-2026-08-06] Half-year results

Peers

Symbol	Summary
TECX	Similar-sized clinical-stage biotech from the packet, but its programs differ. This is only a loose financing and trial-risk reference, not a direct operating or valuation peer.
KYTX	Similar-sized clinical-stage biotech from the packet, but no shared indication or asset economics were verified. It is not a direct operating or valuation peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-02

Loading AI feed…

Symbol

Summary

TECX

Similar-sized clinical-stage biotech from the packet, but its programs differ. This is only a loose financing and trial-risk reference, not a direct operating or valuation peer.

KYTX

Similar-sized clinical-stage biotech from the packet, but no shared indication or asset economics were verified. It is not a direct operating or valuation peer.